Compare NREF & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | ZNTL |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 195.8M |
| IPO Year | N/A | 2020 |
| Metric | NREF | ZNTL |
|---|---|---|
| Price | $13.85 | $6.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $5.80 |
| AVG Volume (30 Days) | 60.5K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.36 | $1.13 |
| 52 Week High | $16.06 | $4.50 |
| Indicator | NREF | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 87.82 |
| Support Level | $13.38 | $1.31 |
| Resistance Level | $14.39 | N/A |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | 0.11 | 0.34 |
| Stochastic Oscillator | 79.04 | 94.98 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.